Skip to main content

Fiscal Wizard · Single-issue tearsheet

LMAT / Jun 22, 2026 Run #7616

LMAT

LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Composite verdict

A 75.7 / 100
Bullish setup · Reversal 7 drivers · 1 gate blocking
  • Accumulation/Distribution Line
  • Wedge Pattern
  • MACD Signal Cross
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 4th of 57 in Medical Instruments & Supplies

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 19 signals0% Bear
Momentum Bullish 61Mean-reversion Bullish 65

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -78%
Asset value $17.22Earnings power value $18.47Price $93.95

Priced above its no-growth earnings power value ($18.47/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

61.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Payout Ratio 99
Earnings Yield 0
PEGY 91
Inventory Turnover 0

Technicals Bullish

90.2 / 100

Bullish setup leads (Accumulation/Distribution Line, Wedge Pattern, MACD Signal Cross); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 88
Wedge Pattern 85
MACD Signal Cross 76

Risk Gates

1 blocking 7 caution

1 guard active, 21 signals gated.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Piotroski F-Score Caution

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Quick Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for LMAT.